Even as other drugmakers are making big plays for business in Japan, India’s Lupin is backing off. Just weeks after selling the sterile manufacturing assets of its Kyowa operation, it has now unloaded the rest of Kyowato a private equity investor.
Lupin today announced it will sell Kyowa Pharmaceutical Industry Co. to Japanese private equity fund Unison for ¥57.4 billion ($526 million) and expects to net about ¥32.6 billion ($300 million) on the deal. Lupin acquired the business in 2007 for about $60 million
The deal includes manufacturing facilities in Sanda and Tottori, Japan and a R&D center at Osaka, Lupin said.
“This transaction is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth in the mid to long-term,” Lupin CEO Vinita Gupta said in a statement. “The deal proceeds will be utilized to strengthen Lupin’s balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets.”
The operation makes a variety of generic products but Lupin said it is particularly strong in the “central nervous system/neurology space.” With about $260 million in sales in fiscal 2019, Lupin said the Kyowa operations ranks fifth in the Japanese generic market.
This deal comes three months after Lupin sold the sterile injectables plant and portfolio of Kyowa to Abu Dhabi-based Neopharma for an undisclosed sum. It also comes as Lupin has been dealing with FDA concerns over some of its manufacturing that will likely require investments. The FDA in September issued a warning letter for Lupin’s finished dose plant in Mandideep, India.
The Lupin Kyowa deal is actually part of a Japan M&A double feature. Novartis’ Sandoz unit announced it is buying the Japanese operations of South Africa’s Aspen Pharmacare for up to €400 million. In that case, Aspen will continue to manufacture drugs for Sandoz for up to seven years. That deal comes as Novartis has yet to complete a $1 billion sale of some plants and a portfolio of 300 drugs to India’s Aurobindo as it tries to remake its exposure in the difficult U.S. generics market.
By Eric Palmer
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
